文献速递细菌感染、耐药与抗菌药物

AxyABM 外排系统过表达在木糖氧化无色杆菌获得性耐药中的作用

Role of AxyABM overexpression in acquired resistance in Achromobacter xylosoxidans.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

研究对一株经氧氟沙星暴露筛选获得的体外耐药突变株 NCF-39-Bo2 及其亲本株 NCF-39 进行 RNA-seq 和全基因组测序,发现突变株中 AxyABM 外排系统过表达约 40 倍,且 AxyR 调控子存在替换;灭活 axyB 后多种抗菌药物 MIC 下降,提示 AxyABM 过表达参与获得性耐药。

要点

  • 体外突变株 NCF-39-Bo2 较亲本株 NCF-39 的 AxyABM 外排系统过表达约 40 倍。
  • NCF-39-Bo2 中检测到 AxyABM 推定调控子 AxyR 的替换。
  • 灭活 NCF-39-Bo2 的 axyB 后,环丙沙星、美罗培南、头孢他啶和头孢地尔 MIC 分别下降 5、64、12、24 倍。

核心结论

  • AxyABM 过表达参与无色杆菌对环丙沙星、美罗培南和头孢他啶的获得性耐药,并提高新药头孢地尔的 MIC。

研究设计与样本

  • 研究对体外耐药突变株 NCF-39-Bo2 及其亲本株 NCF-39 进行 RNA-seq 和全基因组测序,并用基因灭活和 RT-qPCR 探索外排系统的作用。

主要发现

  • NCF-39-Bo2 对美罗培南、头孢他啶、头孢地尔和环丙沙星的 MIC 分别为 8、12、0.094 和 8 mg/L,亲本株 NCF-39 分别为 0.19、3、0.032 和 1.5 mg/L。
  • RNA-seq 显示 NCF-39-Bo2 较亲本株 NCF-39 的 AxyABM 外排系统过表达约 40 倍。
  • NCF-39-Bo2 中检测到 AxyABM 推定调控子 AxyR 的替换。
  • 灭活 NCF-39-Bo2 的 axyB 后,环丙沙星、美罗培南、头孢他啶和头孢地尔 MIC 分别下降 5、64、12 和 24 倍。
  • 灭活临床分离株 AXX-H2 的 axyB 后,上述分子活性增强,尤其是美罗培南。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acquired antimicrobial resistance among Achromobacter isolates from cystic fibrosis (CF) patients is frequent. Data concerning the mechanisms involved are scarce. The role of the AxyXY-OprZ and AxyEF-OprN Resistance Nodulation Division (RND) efflux systems has been demonstrated, but not that of AxyABM. OBJECTIVES: To explore the role of efflux systems in the acquired multiresistance observed in a one-step mutant selected after ofloxacin exposure. METHODS: The in vitro resistant mutant NCF-39-Bo2 and its parental strain NCF-39 (MICs of meropenem of 8 and 0.19 mg/L, of ceftazidime of 12 and 3 mg/L, of cefiderocol of 0.094 and 0.032 mg/L and of ciprofloxacin of 8 and 1.5 mg/L, respectively) were investigated by RNA-seq and WGS. Gene inactivation and reverse transcription quantitative PCR (RT-qPCR) were used to explore the role of the efflux systems of interest. RESULTS: RNA-seq showed that the AxyABM efflux system was overproduced (about 40-fold) in the in vitro mutant NCF-39-Bo2 versus its parental strain NCF-39. A substitution in AxyR, the putative regulator of AxyABM, was detected in NCF-39-Bo2. Gene inactivation of axyB (encoding the transporter component) in NCF-39-Bo2 led to a decrease in MICs of ciprofloxacin (5-fold), meropenem (64-fold), ceftazidime (12-fold) and cefiderocol (24-fold). Inactivation of axyB in the clinical isolate AXX-H2 harbouring a phenotype of resistance close to that of NCF-39-Bo2 enhanced the activity of the same molecules, especially meropenem. CONCLUSIONS: AxyABM overproduction is involved in acquired resistance of Achromobacter to ciprofloxacin, meropenem and ceftazidime, antibiotics widely used in CF patients, and increases the MIC of the new promising antibiotic cefiderocol.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Magallon A, Amoureux L, Garrigos T, et al. Role of AxyABM overexpression in acquired resistance in Achromobacter xylosoxidans. J Antimicrob Chemother. 2022. PMID: 35029278. doi:10.1093/jac/dkab479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。